Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

This includes extensive molecular simulations of the ion channel in its native membrane environment, in open, closed, and inactivated forms, paired with ensemble virtual screening that factors in conformational mobility in each state. Tentative binding pockets are considered in the pore, the gating region, and allosteric areas to capture the full range of mechanisms of action.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q07699

UPID:
SCN1B_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q07699; Q5TZZ4; Q6TN97

BACKGROUND:
The Sodium channel subunit beta-1 is a critical component of voltage-gated sodium channel complexes, essential for proper electrical signaling in the brain, heart, and muscles. It enhances the activity of pore-forming alpha subunits and modulates their gating characteristics. Beyond its electrical role, it serves as a cell adhesion molecule vital for brain development, promoting neuronal migration and neurite outgrowth.

THERAPEUTIC SIGNIFICANCE:
Given its association with diseases such as Generalized epilepsy with febrile seizures plus 1, Brugada syndrome 5, Familial atrial fibrillation 13, and Developmental and epileptic encephalopathy 52, Sodium channel subunit beta-1 presents a promising target for drug discovery. The exploration of its functions and mechanisms offers a pathway to innovative treatments for these complex conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.